Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Michael Roehrle"'
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-11 (2019)
Abstract Background There are currently no approved treatments for the prodromal stage of Alzheimer’s disease (AD). Approved symptomatic treatments for mild-to-moderate AD include acetylcholinesterase inhibitors and memantine, but more efficacious
Externí odkaz:
https://doaj.org/article/360e24efd56d43f9b8a6907e0297c698
Publikováno v:
Alzheimer's Research and Therapy
Alzheimer's Research and Therapy, BioMed Central, 2019, 11, pp.18. ⟨10.1186/s13195-019-0467-2⟩
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-11 (2019)
Alzheimer's Research & Therapy
Alzheimer's Research and Therapy, BioMed Central, 2019, 11, pp.18. ⟨10.1186/s13195-019-0467-2⟩
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-11 (2019)
Alzheimer's Research & Therapy
There are currently no approved treatments for the prodromal stage of Alzheimer’s disease (AD). Approved symptomatic treatments for mild-to-moderate AD include acetylcholinesterase inhibitors and memantine, but more efficacious treatments are neede
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3da640db0e2de5550b82cd76d832bb0c
https://hal.sorbonne-universite.fr/hal-02050512
https://hal.sorbonne-universite.fr/hal-02050512
Publikováno v:
Alzheimer's & Dementia. 14
Publikováno v:
Alzheimer's & Dementia. 12
Autor:
Maria Buti, George Kukolj, Jerry O. Stern, Christoph Sarrazin, Qiqi Deng, Stanislas Pol, Stella Aslanyan, Massimo Puoti, Mitchell L. Shiffman, Massimo Colombo, Filipe Calinas, Richard Vinisko, David R. Nelson, Antonio Olveira, Michael Roehrle, Federico J. Mensa, Pietro Andreone, Francesco Castelli
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Clinical and Experimental Gastroenterology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Clinical and Experimental Gastroenterology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Christoph Sarrazin,1 Francesco Castelli,2 Pietro Andreone,3 Maria Buti,4 Massimo Colombo,5 Stanislas Pol,6 Filipe Calinas,7 Massimo Puoti,8 Antonio Olveira,9 Mitchell Shiffman,10 Jerry O Stern,11 George Kukolj,12 Michael Roehrle,13 Stella Aslanyan,11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491d33053f90bf78b6b9cacdd971ceb5
http://hdl.handle.net/11379/501406
http://hdl.handle.net/11379/501406
Autor:
Jochen Spickerman, Brigitte Roos, Anne Schmitt-Hoffmann, Markus Heep, Michael Roehrle, Tom Brown, Erhard Weidekamm, Jürgen Maares
Publikováno v:
Antimicrobial Agents and Chemotherapy. 50:286-293
BAL8557 is the water-soluble prodrug of BAL4815, a new broad-spectrum antifungal. Healthy male subjects were randomly assigned to four treatment cohorts to receive multiple oral doses or multiple 1-h constant-rate intravenous infusions of BAL8557. Lo
Autor:
Anne Schmitt-Hoffmann, Markus Heep, Erhard Weidekamm, Michael Schleimer, Tom Brown, Brigitte Roos, Christoph Beglinger, Michael Roehrle
Publikováno v:
Antimicrobial agents and chemotherapy. 50(1)
BAL8557 is the water-soluble prodrug of a novel antifungal triazole, BAL4815. BAL4815 is active against a broad spectrum of major opportunistic and pathogenic fungi, including strains that are resistant to other azoles. Cohorts of healthy male subjec